Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-004709
Filing Date
2019-05-09
Accepted
2019-05-09 16:42:22
Documents
79
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bpmc-20190331x10q.htm 10-Q 1797652
2 EX-31.1 bpmc-20190331ex311d750c9.htm EX-31.1 18208
3 EX-31.2 bpmc-20190331ex3121332ab.htm EX-31.2 18240
4 EX-32.1 bpmc-20190331ex3210df481.htm EX-32.1 13848
  Complete submission text file 0001558370-19-004709.txt   6550148

Data Files

Seq Description Document Type Size
5 EX-101.INS bpmc-20190331.xml EX-101.INS 1283691
6 EX-101.SCH bpmc-20190331.xsd EX-101.SCH 52825
7 EX-101.CAL bpmc-20190331_cal.xml EX-101.CAL 60368
8 EX-101.DEF bpmc-20190331_def.xml EX-101.DEF 178497
9 EX-101.LAB bpmc-20190331_lab.xml EX-101.LAB 464708
10 EX-101.PRE bpmc-20190331_pre.xml EX-101.PRE 361493
Mailing Address 45 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 45 SIDNEY STREET CAMBRIDGE MA 02139 617-374-7580
Blueprint Medicines Corp (Filer) CIK: 0001597264 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37359 | Film No.: 19811279
SIC: 2834 Pharmaceutical Preparations